Matilde Imhoff, Magdalena N Diab, Georgina Gallucci, Juan C Stupirski, Ariana Díaz, Bettina Bongiovanni, Diego Bertola, Susana Lioi, Oscar Bottasso, Gabriel A Rabinovich, María L Bay, Luciano D D'Attilio
{"title":"凝集素1和3的调控表达与肺和胸膜结核中失调的T细胞反应有关。","authors":"Matilde Imhoff, Magdalena N Diab, Georgina Gallucci, Juan C Stupirski, Ariana Díaz, Bettina Bongiovanni, Diego Bertola, Susana Lioi, Oscar Bottasso, Gabriel A Rabinovich, María L Bay, Luciano D D'Attilio","doi":"10.1007/s00430-025-00856-w","DOIUrl":null,"url":null,"abstract":"<p><p>Galectins exert a wide range of effects on immune cells in acute and chronic pathologies, although their effects are less described in chronic infections such as tuberculosis-TB. We assessed galectin-1 (Gal-1) and galectin-3 (Gal-3) concentrations and immune mediators in plasma from pulmonary TB-PTB cases (n=38), healthy controls-Hco (n=24), and patients with pleural TB-PLTB (n=11) in which pleural fluid-PLF was also evaluated. Galectin transcripts expression, together with glycosyltransferases, that positively (MGAT5, GCNT1) or negatively (ST6GAL1) control galectins activity, were assessed in mononuclear cells (MC). We also evaluated Gal-1 production, along with other immune-mediators, in Mtb-stimulated MCs. Both patient groups presented elevated circulating levels of pro- and anti-inflammatory mediators and reduced cell proliferation, but a marked T-cell response at the pleural compartment. PTB patients had increased Gal-1 in levels in plasma and higher Gal-1 mRNA levels in MCs (p<0.01, vs. Hco). Both TB groups showed high plasma Gal-3 concentrations and increased expression in MCs (p<0.01 vs. HCo). PLF showed the lowest levels of both galectins, as did their expressions on MCs from pleural effusion. Only PBMCs from PTB exhibited increased expression of GCNT1 (p<0.04) together with diminished ST6GAL1 suggesting enhanced availability of galectin ligands. Mtb-stimulated MCs from both patient groups showed increased Gal-1 production compared to HCo. Moreover, unstimulated cultures from PTB presented a major basal production of Gal-1. Thus, a balance of circulating levels of galectins, pro- and anti-inflammatory mediators, and the differential expression of these lectins as well as glycosylation-related enzymes in MCs, may condition cell function particularly in PTB cases.</p>","PeriodicalId":18369,"journal":{"name":"Medical Microbiology and Immunology","volume":"214 1","pages":"42"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regulated expression of galectins 1 and 3 IS associated with dysregulated T cell responses in pulmonary and pleural tuberculosis.\",\"authors\":\"Matilde Imhoff, Magdalena N Diab, Georgina Gallucci, Juan C Stupirski, Ariana Díaz, Bettina Bongiovanni, Diego Bertola, Susana Lioi, Oscar Bottasso, Gabriel A Rabinovich, María L Bay, Luciano D D'Attilio\",\"doi\":\"10.1007/s00430-025-00856-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Galectins exert a wide range of effects on immune cells in acute and chronic pathologies, although their effects are less described in chronic infections such as tuberculosis-TB. We assessed galectin-1 (Gal-1) and galectin-3 (Gal-3) concentrations and immune mediators in plasma from pulmonary TB-PTB cases (n=38), healthy controls-Hco (n=24), and patients with pleural TB-PLTB (n=11) in which pleural fluid-PLF was also evaluated. Galectin transcripts expression, together with glycosyltransferases, that positively (MGAT5, GCNT1) or negatively (ST6GAL1) control galectins activity, were assessed in mononuclear cells (MC). We also evaluated Gal-1 production, along with other immune-mediators, in Mtb-stimulated MCs. Both patient groups presented elevated circulating levels of pro- and anti-inflammatory mediators and reduced cell proliferation, but a marked T-cell response at the pleural compartment. PTB patients had increased Gal-1 in levels in plasma and higher Gal-1 mRNA levels in MCs (p<0.01, vs. Hco). Both TB groups showed high plasma Gal-3 concentrations and increased expression in MCs (p<0.01 vs. HCo). PLF showed the lowest levels of both galectins, as did their expressions on MCs from pleural effusion. Only PBMCs from PTB exhibited increased expression of GCNT1 (p<0.04) together with diminished ST6GAL1 suggesting enhanced availability of galectin ligands. Mtb-stimulated MCs from both patient groups showed increased Gal-1 production compared to HCo. Moreover, unstimulated cultures from PTB presented a major basal production of Gal-1. Thus, a balance of circulating levels of galectins, pro- and anti-inflammatory mediators, and the differential expression of these lectins as well as glycosylation-related enzymes in MCs, may condition cell function particularly in PTB cases.</p>\",\"PeriodicalId\":18369,\"journal\":{\"name\":\"Medical Microbiology and Immunology\",\"volume\":\"214 1\",\"pages\":\"42\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Microbiology and Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00430-025-00856-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Microbiology and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00430-025-00856-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Regulated expression of galectins 1 and 3 IS associated with dysregulated T cell responses in pulmonary and pleural tuberculosis.
Galectins exert a wide range of effects on immune cells in acute and chronic pathologies, although their effects are less described in chronic infections such as tuberculosis-TB. We assessed galectin-1 (Gal-1) and galectin-3 (Gal-3) concentrations and immune mediators in plasma from pulmonary TB-PTB cases (n=38), healthy controls-Hco (n=24), and patients with pleural TB-PLTB (n=11) in which pleural fluid-PLF was also evaluated. Galectin transcripts expression, together with glycosyltransferases, that positively (MGAT5, GCNT1) or negatively (ST6GAL1) control galectins activity, were assessed in mononuclear cells (MC). We also evaluated Gal-1 production, along with other immune-mediators, in Mtb-stimulated MCs. Both patient groups presented elevated circulating levels of pro- and anti-inflammatory mediators and reduced cell proliferation, but a marked T-cell response at the pleural compartment. PTB patients had increased Gal-1 in levels in plasma and higher Gal-1 mRNA levels in MCs (p<0.01, vs. Hco). Both TB groups showed high plasma Gal-3 concentrations and increased expression in MCs (p<0.01 vs. HCo). PLF showed the lowest levels of both galectins, as did their expressions on MCs from pleural effusion. Only PBMCs from PTB exhibited increased expression of GCNT1 (p<0.04) together with diminished ST6GAL1 suggesting enhanced availability of galectin ligands. Mtb-stimulated MCs from both patient groups showed increased Gal-1 production compared to HCo. Moreover, unstimulated cultures from PTB presented a major basal production of Gal-1. Thus, a balance of circulating levels of galectins, pro- and anti-inflammatory mediators, and the differential expression of these lectins as well as glycosylation-related enzymes in MCs, may condition cell function particularly in PTB cases.
期刊介绍:
Medical Microbiology and Immunology (MMIM) publishes key findings on all aspects of the interrelationship between infectious agents and the immune system of their hosts. The journal´s main focus is original research work on intrinsic, innate or adaptive immune responses to viral, bacterial, fungal and parasitic (protozoan and helminthic) infections and on the virulence of the respective infectious pathogens.
MMIM covers basic, translational as well as clinical research in infectious diseases and infectious disease immunology. Basic research using cell cultures, organoid, and animal models are welcome, provided that the models have a clinical correlate and address a relevant medical question.
The journal also considers manuscripts on the epidemiology of infectious diseases, including the emergence and epidemic spreading of pathogens and the development of resistance to anti-infective therapies, and on novel vaccines and other innovative measurements of prevention.
The following categories of manuscripts will not be considered for publication in MMIM:
submissions of preliminary work, of merely descriptive data sets without investigation of mechanisms or of limited global interest,
manuscripts on existing or novel anti-infective compounds, which focus on pharmaceutical or pharmacological aspects of the drugs,
manuscripts on existing or modified vaccines, unless they report on experimental or clinical efficacy studies or provide new immunological information on their mode of action,
manuscripts on the diagnostics of infectious diseases, unless they offer a novel concept to solve a pending diagnostic problem,
case reports or case series, unless they are embedded in a study that focuses on the anti-infectious immune response and/or on the virulence of a pathogen.